Nkarta(NKTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

NKTX Nkarta

Not Yet Opened 05-06 16:00:00 EDT

3.32

+0.24

+7.79%

盘后3.26

-0.06-1.81%

18:53 EDT

High3.35	Low3.06	Vol1.32M
Open3.13	D1 Closing3.08	Amplitude9.42%
Mkt Cap235.82M	Tradable Cap174.34M	Total Shares71.03M
T/O4.27M	T/O Rate2.52%	Tradable Shares52.51M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"NKTX","market":"US","secType":"STK","nameCN":"Nkarta","latestPrice":3.32,"timestamp":1778097600000,"preClose":3.08,"halted":0,"volume":1321053,"hourTrading":{"tag":"盘后","latestPrice":3.26,"preClose":3.32,"latestTime":"18:53 EDT","volume":3133,"amount":10390.69,"timestamp":1778108004335,"change":-0.06,"changeRate":-0.018072,"amplitude":0.021084},"delay":0,"changeRate":0.07792207792207785,"floatShares":52510907,"shares":71029512,"eps":-1.41,"marketStatus":"Not Yet Opened","change":0.24,"latestTime":"05-06 16:00:00 EDT","open":3.13,"high":3.35,"low":3.06,"amount":4269885.7092255,"amplitude":0.094156,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.41,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1778140800000},"marketStatusCode":0,"adr":0,"listingDate":1594353600000,"exchange":"NASDAQ","adjPreClose":3.08,"preHourTrading":{"tag":"盘前","latestPrice":3.12,"preClose":3.08,"latestTime":"09:29 EDT","volume":536,"amount":1652.41564,"timestamp":1778074199999,"change":0.04,"changeRate":0.012987,"amplitude":0.097045},"postHourTrading":{"tag":"盘后","latestPrice":3.26,"preClose":3.32,"latestTime":"18:53 EDT","volume":3133,"amount":10390.69,"timestamp":1778108004335,"change":-0.06,"changeRate":-0.018072,"amplitude":0.021084},"volumeRatio":1.39999,"impliedVol":1.0303,"impliedVolPercentile":0.804},"requestUrl":"/m/hq/s/NKTX/tweets","defaultTab":"tweets","newsList":[{"id":"2629865761","title":"Nkarta announces annual shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2629865761","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629865761?lang=en_us&edition=fundamental","pubTime":"2026-04-24 04:55","pubTimestamp":1776977725,"startTime":"0","endTime":"0","summary":"Nkarta will hold virtual annual stockholder meeting on June 10, 2026.Director elections set for two Class III nominees, Ali Behbahani and Zachary Scheiner, for terms running to 2029 annual meeting.Advisory vote scheduled on named executive officer compensation.Separate advisory vote planned on frequency of future executive pay votes, with board backing annual cadence.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. nkarta Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 23, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260423:nNDLb4LCMf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTX","BK4139","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627291047","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Biogen (BIIB) and Nkarta (NKTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2627291047","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627291047?lang=en_us&edition=fundamental","pubTime":"2026-04-16 18:40","pubTimestamp":1776336035,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Biogen (BIIB) and Nkarta (NKTX). Biogen (BIIB) In ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-biogen-biib-and-nkarta-nktx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-biogen-biib-and-nkarta-nktx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4505","LU0109394709.USD","BK4137","NKTX","IE00B894F039.SGD","XBI","XLV","HCSG","BK4139","LU0889565916.HKD","BK4532","IE00B19Z9P08.USD","LU0029874061.USD","BK4585","BK4533","LU0320765992.SGD","BK4588","LU0234570918.USD","LU0128526141.USD","IE00B19Z9Z06.USD","BK4581","BIIB","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627230306","title":"Nkarta announces agreement with FDA on changes to Ntrust-1, Ntrust-2 trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2627230306","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627230306?lang=en_us&edition=fundamental","pubTime":"2026-04-16 04:05","pubTimestamp":1776283513,"startTime":"0","endTime":"0","summary":"Nkarta (NKTX) announced that it has reached agreement with the FDA on key changes to the ongoing Ntrust-1 and Ntrust-2 clinical trials. The protoco...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nkarta-announces-agreement-with-fda-on-changes-to-ntrust-1-ntrust-2-trials-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nkarta-announces-agreement-with-fda-on-changes-to-ntrust-1-ntrust-2-trials-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NKTX","LABU","BK4588","BK4585","BK4505","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627237930","title":"Nkarta wins FDA nod for outpatient dosing in NKX019 autoimmune trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2627237930","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627237930?lang=en_us&edition=fundamental","pubTime":"2026-04-16 04:01","pubTimestamp":1776283310,"startTime":"0","endTime":"0","summary":"Nkarta reached FDA agreement to amend Ntrust-1 and Ntrust-2 trials to enable outpatient dosing of investigational CAR-NK therapy NKX019, expanding access to community rheumatology centers.Protocol changes cut required post-dose monitoring to 2 hours from 24 hours, reducing patient burden and supporting broader trial-site participation.Trial design now allows optional re-dosing in both studies to support response optimization.Ntrust-2 will add a rheumatoid arthritis cohort once protocol amendments clear FDA submission and IRB review, widening the autoimmune disease focus.Initial data from ongoing dosing at 4 billion cells per dose are expected to be presented at a medical meeting later this year.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260415:nNDL3Jt3Rm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2T93.GBP","IE00B3QW5Z07.USD","SG9999014039.USD","IE00BGHQF748.EUR","IE00BN0W2W23.USD","BK4505","BK4585","IE00BN0W2V16.EUR","IE00B64PRP62.GBP","IE00BKPKM429.USD","SG9999014013.SGD","LU2210150020.SGD","BK4588","LU2210149790.SGD","NDAQ","SG9999014005.SGD","NKTX","BK4139","BK4112","SG9999014021.USD","LU0314104364.USD","LU2095319765.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627376032","title":"Nkarta Inc - Rheumatoid Arthritis Cohort to Be Added to Ntrust-2 Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2627376032","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627376032?lang=en_us&edition=fundamental","pubTime":"2026-04-16 04:01","pubTimestamp":1776283260,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260415:nTUA1LQJRL:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4505","NKTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627237676","title":"Nkarta Inc - Dosing Continues at 4 Bln Cells per Dose, Data Expected This Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2627237676","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627237676?lang=en_us&edition=fundamental","pubTime":"2026-04-16 04:01","pubTimestamp":1776283260,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260415:nTUA1LQJRL:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4505","BK4139","NKTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627237674","title":"Nkarta Inc - FDA Agrees to Redosing Option in Ntrust-1 and Ntrust-2 Studies","url":"https://stock-news.laohu8.com/highlight/detail?id=2627237674","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627237674?lang=en_us&edition=fundamental","pubTime":"2026-04-16 04:01","pubTimestamp":1776283260,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260415:nTUA1LQJRL:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NKTX","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627237605","title":"Nkarta Inc - FDA Agrees to Outpatient Administration of Nkx019 in Community Settings","url":"https://stock-news.laohu8.com/highlight/detail?id=2627237605","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627237605?lang=en_us&edition=fundamental","pubTime":"2026-04-16 04:01","pubTimestamp":1776283260,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260415:nTUA1LQJRL:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NKTX","BK4505","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626186296","title":"Nkarta to Participate in Needham Virtual Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2626186296","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626186296?lang=en_us&edition=fundamental","pubTime":"2026-04-09 19:00","pubTimestamp":1775732400,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif., April  09, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to tre","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/09/3270795/0/en/Nkarta-to-Participate-in-Needham-Virtual-Healthcare-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HCSG","BK4137","BK4588","LU0029874061.USD","XBI","BK4139","BK4505","BK4585","XLV","LABU","NKTX","LU0128526141.USD","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622952800","title":"Analysts Offer Insights on Healthcare Companies: BioCardia (BCDA) and Nkarta (NKTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2622952800","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622952800?lang=en_us&edition=fundamental","pubTime":"2026-03-28 13:00","pubTimestamp":1774674050,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on BioCardia (BCDA) and Nkarta (NKTX) with bullish sent...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-biocardia-bcda-and-nkarta-nktx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-biocardia-bcda-and-nkarta-nktx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4588","LU0128526141.USD","XBI","BCDA","BK4505","LU0029874061.USD","NKTX","HCSG","XLV","BK4139","BK4581","LABU","BK4137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622857773","title":"Nkarta Is Maintained at Buy by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2622857773","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622857773?lang=en_us&edition=fundamental","pubTime":"2026-03-26 20:31","pubTimestamp":1774528260,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NKTX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 26, 2026 08:31 ET (12:31 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622449852","title":"Nkarta price target raised to $11 from $10 at Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2622449852","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622449852?lang=en_us&edition=fundamental","pubTime":"2026-03-26 19:51","pubTimestamp":1774525879,"startTime":"0","endTime":"0","summary":"Needham raised the firm’s price target on Nkarta (NKTX) to $11 from $10 and keeps a Buy rating on the shares. Published first on TheFly – the ultim...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nkarta-price-target-raised-to-11-from-10-at-needham-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nkarta-price-target-raised-to-11-from-10-at-needham-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NKTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622855196","title":"Nkarta enters at-the-market equity distribution agreement; offering size grows to $100 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2622855196","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622855196?lang=en_us&edition=fundamental","pubTime":"2026-03-26 18:01","pubTimestamp":1774519315,"startTime":"0","endTime":"0","summary":"Nkarta entered into an at-the-market equity distribution agreement with Stifel, Nicolaus & Company for sales of common stock with aggregate gross proceeds of up to USD 100.0 million.Sales may be made from time to time at Nkarta’s discretion, including on the Nasdaq Global Select Market.Stifel will receive a commission of up to 3% of gross sales proceeds from shares sold under the program.The shares will be issued under Nkarta’s Form S-3 registration statement  and a related prospectus supplement.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. nkarta Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Co","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDL3kRYqq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTX","BK4505","BK4127","SF","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622388603","title":"Nkarta Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2622388603","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622388603?lang=en_us&edition=fundamental","pubTime":"2026-03-26 08:55","pubTimestamp":1774486516,"startTime":"0","endTime":"0","summary":"Nkarta Inc reports results for the quarter ended December 31 - Earnings SummaryNkarta Inc NKTX.OQ reported a quarterly adjusted loss of 37 cents per share for the quarter ended December 31, lower than","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nL8N40E00X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTX","BK4505","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622000367","title":"Nkarta Files $350 Million Mixed Shelf","url":"https://stock-news.laohu8.com/highlight/detail?id=2622000367","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622000367?lang=en_us&edition=fundamental","pubTime":"2026-03-26 05:36","pubTimestamp":1774474602,"startTime":"0","endTime":"0","summary":"Nkarta (NKTX) filed a registration statement late Wednesday for the sale of $350 million of securities from time to time.The securities cover common and preferred stocks, debt securities, warrants, rights, and units.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","BK4505","NKTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622000307","title":"Nkarta files $350M mixed securities shelf","url":"https://stock-news.laohu8.com/highlight/detail?id=2622000307","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622000307?lang=en_us&edition=fundamental","pubTime":"2026-03-26 05:25","pubTimestamp":1774473916,"startTime":"0","endTime":"0","summary":"17:24 EDT Nkarta (NKTX) files $350M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-moving breaking fi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nkarta-files-350m-mixed-securities-shelf-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nkarta-files-350m-mixed-securities-shelf-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NKTX","BK4139","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622077150","title":"Nkarta Inc - Files Base Prospectus to Offer up to $350 Mln in Securities - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2622077150","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622077150?lang=en_us&edition=fundamental","pubTime":"2026-03-26 05:24","pubTimestamp":1774473847,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nFWN40D18X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NKTX","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622004017","title":"Nkarta reports Q4 EPS (37c), consensus (29c)","url":"https://stock-news.laohu8.com/highlight/detail?id=2622004017","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622004017?lang=en_us&edition=fundamental","pubTime":"2026-03-26 04:05","pubTimestamp":1774469115,"startTime":"0","endTime":"0","summary":"Nkarta (NKTX) had cash, cash equivalents, restricted cash, and investments in marketable securities of $295.1M as of December 31, 2025. “2025 was a...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nkarta-reports-q4-eps-37c-consensus-29c-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nkarta-reports-q4-eps-37c-consensus-29c-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NKTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622004374","title":"Nkarta Q4 EPS $(0.37) Misses $(0.34) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2622004374","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622004374?lang=en_us&edition=fundamental","pubTime":"2026-03-26 04:02","pubTimestamp":1774468958,"startTime":"0","endTime":"0","summary":"Nkarta (NASDAQ:NKTX) reported quarterly losses of $(0.37) per share which missed the analyst consensus estimate of $(0.34) by 9.79 percent. This is a 5.71 percent decrease over losses of $(0.35) per share from the same","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51468630/nkarta-q4-eps-0-37-misses-0-34-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Nkarta Q4 EPS $(0.37) Misses $(0.34) Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622004376","title":"BRIEF-Nkarta Reports Fourth Quarter And Full Year 2025 Financial Results And Corporate Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2622004376","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622004376?lang=en_us&edition=fundamental","pubTime":"2026-03-26 04:02","pubTimestamp":1774468934,"startTime":"0","endTime":"0","summary":"BRIEF-Nkarta Reports Fourth Quarter And Full Year 2025 Financial Results And Corporate HighlightsMarch 25 (Reuters) - Nkarta Inc NKTX.O:NKARTA REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESUL","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nTUA9SMGWM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","NKTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.nkartatx.com","stockEarnings":[{"period":"1week","weight":0.2342},{"period":"1month","weight":0.4068},{"period":"3month","weight":0.7292},{"period":"6month","weight":0.6939},{"period":"1year","weight":0.7849},{"period":"ytd","weight":0.7946}],"compareEarnings":[{"period":"1week","weight":0.0313},{"period":"1month","weight":0.1137},{"period":"3month","weight":0.083},{"period":"6month","weight":0.0937},{"period":"1year","weight":0.3132},{"period":"ytd","weight":0.0761}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a lymphocyte that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, that is in phase I for the treatment of various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.051655},{"month":2,"riseRate":0.5,"avgChangeRate":0.038672},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.082697},{"month":4,"riseRate":0.666667,"avgChangeRate":0.177626},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.080638},{"month":6,"riseRate":0.2,"avgChangeRate":-0.109268},{"month":7,"riseRate":1,"avgChangeRate":0.107935},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.06764},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.061634},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.060284},{"month":11,"riseRate":0.5,"avgChangeRate":-0.004483},{"month":12,"riseRate":0.333333,"avgChangeRate":0.310979}],"exchange":"NASDAQ","name":"Nkarta","nameEN":"Nkarta"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Nkarta(NKTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Nkarta(NKTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Nkarta,NKTX,Nkarta股票,Nkarta股票老虎,Nkarta股票老虎国际,Nkarta行情,Nkarta股票行情,Nkarta股价,Nkarta股市,Nkarta股票价格,Nkarta股票交易,Nkarta股票购买,Nkarta股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Nkarta(NKTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Nkarta(NKTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction